Overview

Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood

Status:
Not yet recruiting

Trial end date:
2023-07-25

Target enrollment:

Participant gender:

Summary

This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.

Phase:

Phase 4

Details

Lead Sponsor:

National Medical Research Center for Children's Health, Russian Federation

Treatments:

Cyclosporine
Cyclosporins
Methotrexate
Mycophenolic Acid